GLP-1 Informed Consent: What It Should Cover

The consent conversation a clinician owes every patient before the first GLP-1 dose: honest benefit ranges, real risks, alternatives, compounded status, cost, and a plan for stopping.

GLP-1 informed consent should cover six things before the first dose: the expected benefit stated as an honest range, the common and the serious side effects, the alternatives including doing nothing, the compounded-versus-brand distinction when a compounded product is involved, the full cost over time, and the plan for monitoring and for stopping safely. All of it in plain language, before anything is prescribed.

That list is not aspirational. It is the minimum a clinician owes a patient who is about to start a weekly injectable that changes appetite, digestion, and daily routine for months or years. I wrote a companion piece for patients on the questions to ask before starting a GLP-1, and this article is its mirror: the same conversation, seen from the clinician's side of the desk.

What does informed consent actually mean for a GLP-1?

Legally, informed consent means the patient understood the treatment, its risks, and its alternatives well enough to make a real choice. In practice, it is easy to reduce that to a signature on a tablet in the waiting room. A signature protects the clinic. A conversation protects the patient.

In my clinic, consent is a conversation, not a signature. The paperwork exists, but it comes last, after the patient has heard the plan out loud and asked whatever they want to ask. I have noticed something over the years: the patients who understood the plan on day one handle the hard weeks better. When nausea shows up in week three, they say "you told me this might happen, what do we adjust" instead of quitting in silence. When the scale stalls at month five, they remember that we talked about plateaus before they ever started. Understanding is not a courtesy. It is a clinical tool.

How should the benefits be explained honestly?

With a range, not a promise. The trial data is genuinely strong, and it does not need inflation. In STEP-1, semaglutide 2.4 mg averaged about 14.9% body-weight loss at 68 weeks. In SURMOUNT-1, tirzepatide averaged about 20.9% at 72 weeks. Those are averages from brand-name trials: some participants lost considerably more, some lost much less, and a minority responded very little. Results vary by individual, and the patient deserves to hear that sentence before the first dose, not after a disappointing month.

Here is what a fair version sounds like in the room: "The average person in the big semaglutide trial lost about fifteen percent of their body weight over roughly a year and a half. For you, that would be around thirty pounds. You might do better than average, you might do worse, and I will not know which until we are a few months in. What I can promise is that we will measure honestly and adjust." Since brand names come up in every consent conversation, one housekeeping note: Ozempic and Wegovy are trademarks of Novo Nordisk, and Mounjaro and Zepbound are trademarks of Eli Lilly. We are not affiliated with either company.

Which risks belong in the conversation?

Two tiers, and both matter. The common effects first, because the patient will almost certainly meet some of them: nausea, constipation, reflux, fatigue during dose increases, and a noticeable loss of interest in food. I tell patients that these are usually manageable with slower titration, smaller meals, and hydration, and that we adjust the dose rather than push through misery.

Then the rare but serious ones, named plainly: pancreatitis, gallbladder disease, the boxed warning regarding thyroid C-cell tumors seen in rodent studies, and the situations where these medications are not appropriate at all, such as a personal or family history of medullary thyroid carcinoma or MEN2. A patient should also hear the warning signs that mean "call us today":

• Severe abdominal pain, especially pain that radiates to the back
• Persistent vomiting that keeps fluids from staying down
• Signs of dehydration, such as dizziness or very dark urine

Sixty seconds of specifics beats a page of fine print no one reads.

What alternatives must be offered, including doing nothing?

Consent is only real if the patient knows they had options. That means naming the alternatives even when the patient walked in asking for a GLP-1 by name: structured nutrition and activity programs, older oral medications where appropriate, bariatric surgery for some candidates, and the honest option of doing nothing for now.

Doing nothing is a legitimate choice, and it has its own risk profile - continued weight-related health effects - which deserves the same plain description as the drug's side effects. When I walk through alternatives, some patients still choose the medication, some choose to start with three months of foundational work first, and a few decide the timing is wrong. Every one of those is a good outcome, because the decision belonged to the patient.

What must consent say about compounded medications?

If a clinic uses compounded semaglutide or tirzepatide, the consent conversation is exactly where that fact belongs, stated without hedging: compounded versions are not FDA-approved and are not identical to the brand-name products. They are prepared by compounding pharmacies under a different regulatory pathway, they have not gone through the brand products' approval trials, and results vary by individual.

In the room, it sounds like this: "What I am offering is compounded. It is not the brand pen you have seen advertised. The FDA has not reviewed or approved this specific preparation, and I cannot tell you it will behave identically. Here is why I use this pharmacy, here is how the product is tested, and here is what the brand alternative would cost if you prefer it." A patient who hears that and proceeds has genuinely consented. A patient who finds out later, from a news story or a pharmacist, has not - and understandably feels let down by a conversation that skipped the sentence.

Why do cost and the exit plan belong in consent?

Because money is a side effect. A treatment that runs for many months at a real monthly price is a financial commitment, and a patient who cannot sustain it will face an unplanned stop - which is the worst way to stop. Good consent covers the total expected cost, what happens if the price changes, and what the patient is paying for beyond the vial: visits, labs, dose management, and support.

The exit plan deserves equal billing. Before the first injection, the patient should know that stopping abruptly often leads to appetite returning and weight regaining, that tapering and maintenance strategies exist, and that the clinic will manage the off-ramp rather than simply cancel a subscription. A medication with a beginning and no planned ending is not a plan.

What standard should patients expect from any clinic?

This one. Nothing in this article is proprietary, and that is the point. The field of obesity medicine is converging on exactly this kind of consent conversation, and any good clinic - including ones that compete with mine - can meet this standard and be proud of it. Patients are becoming better informed, which makes every honest practice look better and makes the whole field more trustworthy.

If you are considering treatment, bring the patient-side checklist with you and expect a clinician who welcomes it. A doctor who is glad you asked is telling you something important before the first dose is ever drawn.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.